Cidara Therapeutics, Inc.: 5%+ holders

Cidara Therapeutics, Inc. has 25 Schedule 13D or 13G filings on record since 2025-07-02. 1 holder's latest filing reports 5% or more of common stock, $0.0001 par value per share. Each figure below is the holder's own, as filed, with the filing linked.

Holders

Purpose of Transaction (Item 4)

RA Capital Management, L.P.

Item 4 of the Statement is hereby amended and supplemented as follows: The Offer and withdrawal rights expired as scheduled at one minute following 11:59 p.m., Eastern Time, on January 6, 2026 (such date and time, the "Expiration Time"). As of the Expiration Time, a sufficient number of shares were validly tendered and not validly withdrawn such that the minimum tender condition to the Offer was satisfied, and following the satisfaction of each other condition to the Offer, Parent and Purchaser irrevocably accepted for payment, on January 7, 2026, all shares that were validly tendered and not validly withdrawn pursuant to the Offer. Also on January 7, 2026, following consummation of the Offer, Purchaser merged with and into the Issuer, with the Issuer being the surviving corporation (the "Merger"). The Merger was governed by Section 251(h) of the Delaware General Corporation Law (the "DGCL"), with no vote of the stockholders of the Issuer required to consummate the Merger. Upon completion of the Merger, the Issuer became a wholly owned subsidiary of Parent, the Issuer's common stock was deregistered under the Securities and Exchange Act of 1934, as amended, and the Issuer's common stock ceased to be listed for trading on the Nasdaq Stock Market. At the Effective Time and pursuant to the terms and conditions of the Merger Agreement, each Common Share then outstanding (other than Common Shares (a) held by the Issuer (or in the Issuer's treasury), Parent, Purchaser, any …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-01-09; the filing has the rest

Timeline

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes